Table 1 |
||||
|
Clinical and serological features of patients by study group |
||||
|
Characteristics |
Rhupus |
RA |
SLE |
Controls |
|
|
||||
|
Number of patients |
7 |
7 |
7 |
7 |
|
Median age, years (range) |
44 (25–64) |
46 (31–61) |
41 (24–66) |
41 (28–63) |
|
Median age of onset, years (range) |
26 (11–61) |
40 (27–45) |
39 (18–52) |
- |
|
SLE criteria, n (percentage) |
||||
|
Malar rash |
5 (71) |
- |
7 (100) |
- |
|
Discoid lupus |
1 (14) |
- |
1 (14) |
- |
|
Photosensitivity |
4 (57) |
- |
5 (71) |
- |
|
Oral ulcers |
5 (71) |
- |
5 (71) |
- |
|
Serositis |
3 (43) |
- |
0 (0) |
- |
|
Renal |
2 (29) |
- |
2 (29) |
- |
|
Neurological |
1 (14) |
- |
1 (14) |
- |
|
Hematological |
7 (100) |
- |
6 (86) |
- |
|
Immunological |
4 (57) |
- |
5 (71) |
- |
|
ANA |
7 (100) |
- |
7 (100) |
- |
|
RA criteria, n (percentage) |
||||
|
Morning stiffness |
3 (43) |
5 (71) |
- |
- |
|
Arthritis in more than three areas |
7 (100) |
7 (100) |
- |
- |
|
Arthritis of hands |
7 (100) |
7 (100) |
- |
- |
|
Symmetric arthritis |
7 (100) |
7 (100) |
- |
- |
|
Rheumatoid nodules |
0 (0) |
3 (43) |
- |
- |
|
RF |
5 (71) |
6 (86) |
- |
- |
|
X-ray changes |
7 (100) |
7 (100) |
- |
- |
|
Serology, n (percentage) |
||||
|
Anti-CCP |
4 (57) |
6 (86) |
0 (0) |
0 (0) |
|
ANA |
7 (100) |
0 (0) |
7 (100) |
2 (29) |
|
Anti-dsDNA |
4 (57) |
0 (0) |
4 (57) |
0 (0) |
|
Anti-SSA |
4 (57) |
0 (0) |
3 (43) |
1 (14) |
|
Anti-SSB |
1 (14) |
0 (0) |
1 (14) |
0 (0) |
|
Anti-Sm |
1 (14) |
0 (0) |
2 (29) |
0 (0) |
|
Anti-RNP |
1 (14) |
0 (0) |
2 (29) |
0 (0) |
|
RF |
5 (71) |
6 (86) |
2 (29) |
1 (14) |
|
|
||||
|
ANA, antinuclear antibodies; anti-CCP, antibodies against cyclic citrullinated peptides; anti-dsDNA, antibodies against double-stranded DNA; anti-RNP, antibodies against ribonucleoprotein; RA, rheumatoid arthritis; RF, rheumatoid factor; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome. |
||||
|
Amezcua-Guerra et al. Arthritis Research & Therapy 2006 8:R144 doi:10.1186/ar2036 |
||||
